|
Directory of 2001
New Drug Releases
a = 1st quarter, b = 2nd quarter,
c = 3rd quarter, d = 4th quarter
|
Date |
Generic |
Trade |
Manufacturer |
Indication |
Class |
|
2001d |
Darbepoetin |
Aranesp |
Amgen |
Anemia |
Hematology |
|
2001d |
Budesonide EC |
Entocort EC |
AstraZeneca |
Crohn’s Disease |
Gastrointestinal |
|
2001c |
Alemtuzumab |
Campath |
Berlex |
Monoclonal antibody for B-CLL |
Oncology |
|
2001c |
Almotriptan |
Axert |
Pharmacia |
Migraine |
Neurology |
|
2001c |
Esomeprazole |
Nexium |
Astra-Zeneca |
Proton-pump inhibitor for GERD |
Gastrointestinal |
|
2001c |
Imatinib |
Gleevec |
Novartis |
Chronic myeloid leukemia |
Oncology |
|
2001c |
Nesiritide |
Natrecor |
Scios |
Vasodilator for acute CHF |
Cardiology |
|
2001c |
Zoledronic
acid |
Zometa |
Novartis |
Hypercalcemia of malignancy |
Oncology |
|
2001b |
Bivalirudin |
Angiomax |
Medicines Company |
Anticoagulant prior to PTCA |
Hematology |
|
2001b |
Caspofungin |
Cancidas |
Merck |
Antifungal for aspergillosis |
Antiinfective |
|
2001b |
Formoterol |
Foradil |
Novartis |
Beta-2-agonist, long-acting |
Respiratory |
|
2001b |
Galantamine |
Reminyl |
Janssen |
Alzheimer's Disease |
Neurology |
|
2001b |
Insulin glargine |
Lantus |
Aventis |
Long-acting insulin |
Diabetes |
|
2001b |
Nateglinide |
Starlix |
Novartis |
Diabetes Type II |
Diabetes |
|
2001b |
Ziprasidone |
Geodon |
Pfizer |
Schizophrenia |
Psychiatry |
|
2001a |
Aminolevulinic acid |
Levulan |
Berlex
|
Actinic keratoses "Kerastick" |
Dermatology |
|
2001a |
Arsenic Trioxide |
Trisenox |
Cell Therapeutics |
Acute Promyelocytic Leukemia |
Oncology |
|
2001a |
Balsalazide |
Colazal |
Salix |
Ulcerative colitis |
Gastrointestinal |
|
2001a |
Docosanol |
Abreva |
Glaxo-Wellcome |
OTC treatment for Cold sores |
Antiinfective |
|
2001a |
Eflornithine |
Vaniqa |
BristolMyersSquibb |
Removes unwanted facial hair |
Dermatology |
|
2001a |
Lopinavir/Ritonavir |
Kaletra |
Abbott |
Protease inhibitor for HIV infection |
HIV/AIDS |
|
2001a |
Pemirolast |
Alamast |
Santen |
Allergic conjunctivitis |
Ophthalmology |
Notice to reader:
The intent of these drug reviews is to provide a condensed summary of new drug
information. While care and effort have been made to ensure these monographs
contain the most significant and pertinent information, the author and publisher
is not responsible for omissions, lack of completeness, or errors. Readers are
urged to refer to the complete prescribing information available in the package
insert and other appropriate sources for further information. Because the field
of health care is constantly evolving and there are numerous changes in drug
therapy, readers are advised to regularly consult the current drug literature
and available drug information resources.
© 2001 New Drug
Pocket Briefs
|
